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Over more than two decades, the concept 
of atherosclerosis has developed and lead 
to inflammatory hypothesis. Inflammation 
plays an important role on pathogenesis of 
atherothrombosis and coronary heart disease 
(CHD), including acute coronary syndrome 
(ACS).1,2
One of inflammatory markers, C-reactive 
protein (CRP), is a biomarker for the acute-
phase of inflammatory response, which is 
produced by hepatocytes through stimulation 
of pro-inflammatory cytokines, particularly 
interleukin-6 (IL-6). It is associated with an 
increased cardiovascular risk in patients with 
previous history of atherosclerosis. Some studies 
have reported that the increase of CRP level is 
an independent prognostic marker for recurrent 
and non-fatal myocardial infarct (MI) or death 
due to cardiac diseases.3,4
Gal-3 is a marker involved in fibrosis, 
inflammation and reconstruction of cardiac 
tissue. Some studies have demonstrated that 
there is an elevated level of systemic Gal-3 in 
the events of acute myocardium infarct (AMI).5 
Meanwhile, myeloperoxidase (MPO) is 
a proteolytic enzyme released by activated 
neutrophils and is considered as a systemic 
marker of neutrophils activation.6 In ST-elevation 
myocardium infarct (STEMI), the plasma level 
of MPO shows a biphasic response with a peak 
at the early stage immediately before primary 
coronary intervention (PCI) takes place and the 
second peak occurs at 24 hours after reperfusion.7 
MPO is also independently associated with 
hospital mortality in a population of patients 
with STEMI.8
Although the management of ACS has been 
demonstrated to be beneficial for secondary 
prevention of coronary heart disease (such as 
using statin and aspirin) and also seemed to have 
positive effect on inflammation, the identification 
of effective management, specifically targeting 
inflammation, has been not been comprehensively 
understood.9
The Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study (CANTOS) 
supported targeting inflammation as a potential 
effective treatment for chronic coronary heart 
disease. In the CANTOS study, canakinumab, 
a monoclonal antibody that inhibits interleukin-
1β, reduced the level of hsCRP and caused 
lower risk of composite endpoint of death due 
to cardiovascular diseases, myocardial infarct or 
stroke compared to placebo.10
However, non-specific anti-inflammatory 
t r ea tment  us ing  metho t rexa te  in  the 
Cardiovascular Inflammation Reduction Trial 
(CIRT) study did not show any reduced hsCRP 
and demonstrated that there is no benefit 
associated with cardiovascular outcomes,11 
which left us with a question whether direct 
intervention on inflammation could improve 
cardiovascular outcomes.
Acetylcys te ine ,  a  th io l -conta in ing 
Idrus Alwi                                                                                                                       Acta Med Indones-Indones J Intern Med
288
antioxidant, is often used to treat various 
pulmonary diseases and acute acetaminophen 
intoxication.12 Some studies have reported that 
administration of NAC, in combination with 
NTG and streptokinase, was associated with 
significantly less oxidative stress, a trend toward 
more rapid reperfusion, and better preservation of 
left ventricular function in patients with evolving 
acute myocardial infarction.13 Sochman et al14 
reported that patients treated with streptokinase 
and NAC (100 mg/kg) had significantly more 
favourable values of the monitored parameters 
than those treated with streptokinase alone.
Trisulo et al.15 reported the effect of 600 mg 
N-acetylcysteine (NAC) supplementation 3 times 
daily for 3 days on immune system of patients 
with AMI. The investigators randomly included 
32 AMI patients with ST segment elevation 
(STEMI) who received fibrinolytic treatment: 
17 patients received standard therapy and 600 
mg of oral NAC every 8 hours for 3 days and 15 
patients received standard therapy as the control. 
The levels of high sensitivity C-reactive protein 
(HsCRP), MPO, and Galectin-3 of both groups 
were evaluated at admission and after 72 hours of 
care. Data regarding those receiving PCI and statin 
treatment in both groups were not being reported.
At admission, there was no significant 
difference regarding HsCRP, MPO, and Gal-
3 levels between NAC and control group; 
while after 72 hours receiving NAC treatment, 
the levels of HsCRP, MPO, and Gal-3 were 
significantly lower in the treatment group 
compared to the control group. In the NAC 
group, after 72 hours compared to at admission, 
there were significant differences of HsCRP, 
MPO, and Gal-3 levels; while in the control 
group, such differences were not found. There 
were significant differences on HsCRP, MPO 
and Gal-3 levels between the NAC and control 
groups; therefore, it is concluded that oral 600 
mg NAC supplementation every 8 hours for 72 
hours can lower HsCRP, MPO and Gal-3 levels 
in AMI patients receiving fibrinolytic therapy. 
Data about side effects had not been reported 
in the study.
Results of the study has provided additional 
evidence that inflammatory and immune system 
targeting drugs can lower the levels of some 
inflammatory and fibrosis markers. It opens 
greater opportunity for further studies to provide 
evidences whether those drugs are also beneficial 
in reducing cardiovascular outcome in ACS 
patients without causing side effects. Whether 
NAC can be used as additional therapy to provide 
better management of AMI or not, still needs 
further studies with bigger sample size of patients 
to evaluate the effect of NAC on cardiovascular 
morbidity and mortality.
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